Thomas R. Pieber

Graz, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 333 publications

Mid-infrared wearable biosensing for metabolic syndrome: Opportunities and translational challenges.

Mid-infrared wearable biosensing for metabolic syndrome: Opportunities and translational challenges.

Journal: iScience

Published: July 23, 2026

Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec.

Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec.

Journal: Diabetes, obesity & metabolism

Published: April 23, 2026

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic Syndrome Spectrum: A Narrative Review.

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic Syndrome Spectrum: A Narrative Review.

Journal: Obesity facts

Published: April 02, 2026

A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI.

A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI.

Journal: Diabetes, obesity & metabolism

Published: March 30, 2026

Glycemic Efficacy and Safety by Using Insulin Degludec and Aspart Guided by a Clinical Decision Support System in Non-Critically Ill Inpatients with Type 2 Diabetes Mellitus.

Glycemic Efficacy and Safety by Using Insulin Degludec and Aspart Guided by a Clinical Decision Support System in Non-Critically Ill Inpatients with Type 2 Diabetes Mellitus.

Journal: Biosensors

Published: March 18, 2026

Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures.

Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures.

Journal: Diabetes care

Published: March 09, 2026

Clinical Characteristics and Predictors of Glycemic Control During the First 24 Months After Diagnosis of Type 1 Diabetes.

Clinical Characteristics and Predictors of Glycemic Control During the First 24 Months After Diagnosis of Type 1 Diabetes.

Journal: Biomedicines

Published: February 18, 2026

Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)

Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)

Journal: Wiener klinische Wochenschrift

Published: January 02, 2026

Presenilin-1 controls glycolysis and identity of pancreatic beta cells.

Presenilin-1 controls glycolysis and identity of pancreatic beta cells.

Journal: Communications biology

Published: December 22, 2025

The use of diabetes technology under aviation conditions: A systematic review of human and in-vitro studies and future considerations.

The use of diabetes technology under aviation conditions: A systematic review of human and in-vitro studies and future considerations.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: November 25, 2025

Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges.

Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges.

Journal: Cancer treatment reviews

Published: November 17, 2025

In-flight glycaemic control using automated insulin delivery systems: A within-subject comparative pilot study.

In-flight glycaemic control using automated insulin delivery systems: A within-subject comparative pilot study.

Journal: Diabetes, obesity & metabolism

Published: November 02, 2025

Showing 1-12 of 333

Last Updated: 09/26/2026